MDACC Study No:2006-0620 ( NCT No: NCT00506155)
Title:A Phase II Clinical Trial of Neoadjuvant Chemotherapy with M-VAC Plus Avastin in Patients with Locally Advanced Urothelial Cancer.
Principal Investigator:Arlene Siefker-Radtke
Treatment Agent:Avastin; Cisplatin; Doxorubicin; Methotrexate; Vinblastine Sulfate
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn how well bladder cancer
responds to a combination treatment with Avastin and M-VAC (methotrexate,
doxorubicin, vinblastine, and cisplatin) before surgery to remove the tumor.
Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase II
Treatment Agents:Avastin
Vinblastine Sulfate
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Treatment can be given as inpatient or outpatient at the investigator's
discretion. Length of stay will vary.
Supported By:N/A
Return Visit:Patients will return every 2 weeks for chemotherapy.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Arlene Siefker-Radtke
Dept:Genitourinary Medical Oncology
For Clinical Trial Enrollment:713-792-2830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults